Health and Pharma’s Post

Exciting news in the world of cancer treatment! Check out this article about the new first-line treatment for advanced bladder urothelial cancer. Learn more here. 👉 https://zurl.co/ly6O #GHPNews #CancerTreatment #BladderCancer #MedicalAdvancements

Preliminary data from the Phase III IMforte trial show the combination of Zepzelca (lurbinectedin) plus Tecentriq (atezolizumab) significantly improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer.

We’re making significant progress in the fight against #lungcancer. Today at #ASCO24, we shared important results from our Phase 3 clinical trial evaluating treatments for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). After five years of median follow-up, one of our treatments showed unprecedented progression-free survival, with 60% of patients alive without disease worsening.   Lung cancer is the #1 cause of cancer-related death around the world. We have spent years at Pfizer working on developing potential solutions that can help people with cancer live better and longer lives. These results represent Pfizer’s commitment to advancing outcomes for patients.   https://lnkd.in/exjYrybQ

With great pride and joy, I’d like to share a milestone moment we at #Pfizer have experienced in the last 12 hours. At the #ASCO24, we announced groundbreaking results from the 5-year follow up of our Phase 3 CROWN study for ALK+ advanced Non-Small Cell Lung Cancer (NSCLC). The study revealed that 60% of patients achieved 5 years of progression-free survival (PFS) with one of our treatments. In the words of the investigators and Lung Cancer experts, this is unprecedented. As highlighted in the Journal of Clinical Oncology (https://lnkd.in/gw35YHs5), ‘This is the longest PFS ever reported with any single-agent targeted treatment not only in advanced NSCLC but across all metastatic solid tumors’. The significant impact this can have on the quality of life for patients with ALK+ NSCLC and their families is truly humbling. At Pfizer, we are committed to bring breakthrough solutions in oncology and across therapeutic areas to help patients live better and longer lives. Read more at : https://lnkd.in/gJqBNsfW #PFEColleague #CancerResearch #LungCancer #letsoutdocancer 

There’s still considerable potential for TROP2 ADC development.

Early data suggests that bispecific antibody petosemtamab, in conjunction with Keytruda, generates a 60% response rate in patients with second-line head and neck cancer. However, more mature clinical data will give us a clearer picture of how accurate this is. Get in touch to discover how evitria can support your antibody needs. #Biotech #BispecificAntibodies #Antibodies #HeadAndNeckCancer

🎗️🧫Another significant development in targeted therapy - this one for HER2-positive tumor types. Although HER2-positive appendiceal tumors are very rare, this development is (1) a demonstration of the evolution of cancer treatments more broadly; and (2) a welcome addition to treatment options for any patient who happens to have HER2-positive appendiceal cancer. https://lnkd.in/eG5fAdj7

Very exciting findings today from World Lung. Phase 3 results from China showing marked PFS enhancement by PD1 x VEGF bispecific (ivonescimab) vs Keytruda (11.14 months vs 5.32 months, 49% reduction of risk for progression or death). Magnitude of benefit reported to be consistent across key patient subgroups. Overall survival data is TBD. Will likely require a global trial prior to an approval by FDA, but really strong result, with yet another bispecific approach for cancer immunotherapy for solid tumors in addition to the broad success that has been building for several years with the treatment of patients with hematologic malignancies. #cancer #oncology #immunooncology #immunotherapy #cancerimmunotherapy #drugdevelopment

A significant advancement in the fight against #gastric #cancer! Astellas Pharma' innovative therapy has received approval from UK regulators, marking a new milestone in targeted cancer treatment. This development brings renewed hope to #patients battling gastric cancer, offering more effective treatment options and improving outcomes. Staying informed about the latest therapies is crucial in our ongoing mission to provide the best care possible. As the global oncology landscape evolves, we remain committed to adopting cutting-edge solutions that bring us closer to a cancer-free world. Read more at: https://lnkd.in/gM3qTWev #Oncology #CancerTreatment #GastricCancer #MedicalInnovation #CancerCare #DubaiOncology #PatientCare #HealthcareInnovation #CancerResearch